Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention

Circulation Journal

Volumn 68, Issue 10, 2004, Pages 928-932

  Lim, Sang Yup ^a   Bae, Eun Hui ^a   Jeong, Myung Ho ^a   Kang, Dong Goo ^a   Lee, Yeon Sang ^a   Kim, Kye Hun ^a   Lee, Sang Hyun ^a   Yoon, Kyung Ho ^a   Hong, Seo Na ^a   Park, Hyung Wook ^a   Hong, Young Joon ^a   Kim, Ju Han ^a   Kim, Weon ^a   Ahn, Young Keun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Adenosine; Coronary disease; Myocardial infarction; Nicorandil

Indexed keywords

ABCIXIMAB; ADENOSINE; NICORANDIL; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY DISSECTION; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE WALL MOTION; HUMAN; MALE; MORTALITY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; SCORING SYSTEM; THROMBOSIS; TIME;

ADENOSINE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NICORANDIL; TREATMENT OUTCOME;

EID: 7044233459     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.928     Document Type: Article

References (32)

1. Mehta NJ, Khan IA. Cardiology's 10 greatest discoveries of the 20th century. Tex Heart Inst J 2002; 29: 164-171.
2. Piana RN, Paik GY, Moscucci M. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
3. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
4. Kloner RA, Ganote CE, Jennings RB, Reimer KA. Demonstration of the 'no-reflow' phenomenon in the dog heart after temporary ischemia. Recent Adv Stud Cardiac Struct Metab 1975; 10: 463-474.
5. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995; 75: 778-782.
6. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno ML, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-46.
7. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130: 239-243.
8. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959-963.
9. Reffelmann T, Kloner RA. Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 2004; 43: 580-588.
10. Ozdemir M, Cemri M, Yalcin R, Cengel A. Use of intracoronary adenosine for the management of slow-no-reflow phenomenon during percutaneous interventions. Cathet Cardiovasc Interv 2001; 54: 267-268.
11. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J 2002; 66: 1119-1123.
12. Sakata Y, Kodama K, Ishikura F, Komamura K, Hasegawa S, Sakata Y, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997; 61: 455-458.
13. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. Circ J 2002; 66: 411-415.
14. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circ J 2002; 66: 317-322.
15. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
16. Aguirre FV, McMahon RP, Mueller H, Kleiman NS, Kern MJ, Hamilton WP, et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy: Results from the TIMI II Study. Circulation 1994; 90: 78-86.
17. Ho H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-1705.
18. Reffelmann T, Kloner RA. Microvascular reperfusion injury: Rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol 2002; 283: H1099-H1107.
19. Nanobashvili J, Neumayer C, Fuegl A, Blumer R, Prager M, Sporn E, et al. Development of 'no-reflow' phenomenon in ischemia/reperfusion injury: Failure of active vasomotility and not simply passive vasoconstriction. Eur Surg Res 2003; 35: 417-424.
20. Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002; 106: 1672-1677.
21. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion injury on clinical outcome. Circulation 1999; 99: 1972-1977.
22. Entman ML, Smith CW. Post reperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994; 28: 1301-1311.
23. Bremerich J, Wendland MF, Arheden H, Wyttenbach R, Gao DW, Huberty JP, et al. Microvascular injury in reperfused infarcted myocardium: Noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging. J Am Coll Cardiol 1998; 32: 787-793.
24. Hamada S, Nakamura S, Sugiura T, Murakami T, Fujimoto T, Watanabe J, et al. Early detection of the no-reflow phenomenon in reperfused acute myocardial infarction using technetium-99m tetro-fosmin imaging. Eur J Nucl Med 1999; 26: 208-214.
25. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-888.
26. Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty: RAPPORT investigators (ReoPro And Primary PTCA Organization and Randomized Trial). Am J Cardiol 1999; 84: 728-730.
27. Nolte D, Lehr HA, Messmer K. Adenosine inhibits postischemic leukocyte-endothelium interaction in postcapillary venules of the hamster. Am J Physiol 1991; 261: H651-H655.
28. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-1720.
29. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon. Cathet Cardiovasc Interv 2000; 51: 27-31.
30. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-2159.
31. Louis AA, Manousos IR, Coletta AP, Clark AL, Cleland JG. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH (Impact Of Nicorandil on Angina; Combination Assessment of Ranolazine In Stable Angina; ENhancing Recovery In Coronary Heart Disease patients; Assessment of cardioversion using transoesophageal echocardiography; AzimiLide post-Infarct surVival Evaluation; Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure). Eur J Heart Fail 2002; 4: 111-116.
32. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K (ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1339-1346.